IBio Reports Encouraging Data From Non-human Primate Study Of IBIO-600
(RTTNews) - iBio, Inc. (IBIO) Monday reported encouraging data from a non-GLP non-human primate (NHP) pharmacokinetics study of the company's lead drug candidate IBIO-600 for the treatment of obesity. The study was designed to evaluate the potential of IBIO-600 in NHPs by determining the antibody's half-life in serum and analyzing changes in lean and fat mass. Data from the study suggests that IBIO-600 could have a human half-life as long as 130 days. Further, IBIO-600 promoted a dose-dependent increase in lean mass and a reduction in fat mass from baseline values.
iBio is on track for a regulatory submission for IBIO-600 in the first quarter of 2026.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.